Actively Recruiting
Antihistamine for Prevention of HTR After Blood Primed CPB
Led by Kasr El Aini Hospital · Updated on 2026-04-21
40
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
K
Kasr El Aini Hospital
Lead Sponsor
M
Misr University for Science and Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will be a randomized, double-blinded, placebo-controlled study conducted at a university hospital. Forty children undergoing elective repair of a congenital heart defect will be included. The patients will be randomly allocated (20 patients per group) to receive a single intravenous dose of combined chlorpheniramine or normal saline immediately after separation from CPB, before protamine administration.
CONDITIONS
Official Title
Antihistamine for Prevention of HTR After Blood Primed CPB
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acyanotic congenital heart disease
- Age between 1 and 7 years
- Both genders included
You will not qualify if you...
- Previous heart surgery (redo patient)
- Allergy to antihistamines
- Bleeding disorders with INR greater than 1.5 and/or platelets less than 50,000
- Emergency procedure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Misr Universty for Scince and Technology
Giza, October, Egypt, 12582
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here